Analyst rating accuracy & track record
Mayank Mamtani is an equity research analyst at B. Riley Securities. Bullish Whales has scored 24 of their stock calls across 19 companies. Their picks beat their sector 54% of the time over the next 12 months, and their price targets were reached 38% of the time within a year.
Track record
Bullish Whales has scored 24 of Mayank Mamtani's stock calls across 19 companies, dating back to 2020. Their rated stocks beat their own sector 54% of the time over the next 12 months. On a typical call, a Mamtani pick returned +12.6% more than its sector over the following year.
Of the scored calls, 24 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.
Coverage & ratings
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 MDGLMadrigal Pharmaceuticals Inc | Buy | $460.00 | May 2025 | +62.6% | Hit |
 TRVITrevi Therapeutics Inc | Buy | $20.00 | Mar 2025 | +60.4% | Miss |
 DNLIDenali Therapeutics Inc | Buy | $35.00 | Mar 2025 | +16.2% | Miss |
 ARWRArrowhead Pharmaceuticals Inc | Buy | $38.00 | Feb 2025 | +200.8% | Hit |
 VKTXViking Therapeutics Inc | Buy | $96.00 | Feb 2025 | −11.6% | Miss |
 NKTRNektar Therapeutics | Buy | $4.00 | Jan 2025 | +153.0% | Hit |
 NVAXNovavax Inc | Buy | $26.00 | Oct 2024 | −27.5% | Miss |
 CNTACentessa Pharmaceuticals PLC ADR | Buy | $33.00 | Sep 2024 | +47.5% | Miss |
 ALTAltimmune Inc | Buy | $20.00 | Aug 2024 | −30.9% | Miss |
 TGTXTG Therapeutics Inc | Buy | $34.00 | Aug 2024 | +51.3% | Hit |
| ALTAltimmune Inc | Buy | $20.00 | Jun 2024 | +30.1% | Miss |
| TGTXTG Therapeutics Inc | Buy | $29.00 | Feb 2024 | +110.7% | Hit |
| TGTXTG Therapeutics Inc | Buy | $24.00 | Oct 2023 | +243.5% | Hit |
 SCLXScilex Holding Company | Buy | $4.00 | Oct 2023 | −77.1% | Miss |
 XFORX4 Pharmaceuticals Inc | Buy | $3.00 | Apr 2023 | +24.9% | Miss |
 FBIOFortress Biotech Inc | Buy | $6.00 | Jul 2022 | −43.0% | Miss |
| XFORX4 Pharmaceuticals Inc | Buy | $7.00 | May 2022 | +78.2% | Miss |
 MBIOMustang Bio Inc | Buy | $6.00 | Jan 2022 | −48.7% | Miss |
 INMBINmune Bio Inc | Buy | $20.00 | Jan 2022 | −22.4% | Miss |
 BIVIBiovie Inc | Buy | $27.00 | Nov 2021 | +5.1% | Miss |
 FWONKLiberty Media Corporation Series C Liberty Formula One Common Stock | Buy | $39.00 | Mar 2020 | +14.8% | Hit |
| FBIOFortress Biotech Inc | Buy | $6.00 | Mar 2020 | +231.8% | Miss |
 GLMDGalmed Pharmaceuticals Ltd | Buy | $11.00 | Mar 2020 | −41.4% | Miss |
 MNOVMediciNova Inc | Buy | $11.00 | Mar 2020 | +22.3% | Hit |
Mayank Mamtani: analyst track record FAQ
Is Mayank Mamtani a good stock analyst?
Yes, by track record. Mayank Mamtani ranks number 4 of 347 of the analysts Bullish Whales scores, with a BW Score of 88 out of 100. Their edge holds up after we account for testing thousands of analysts at once, so they clear our Skilled bar. Past results do not guarantee future ones.
What is Mayank Mamtani's win rate?
Mayank Mamtani's win rate is 54%. Across 24 scored calls, their rated stocks beat their sector 54% of the time over the next 12 months. On a typical call they returned +12.6% more than the sector.
What stocks and sectors does Mayank Mamtani cover?
Mayank Mamtani covers 19 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.
Are Mayank Mamtani's price targets accurate?
Mayank Mamtani's price targets are reached within 12 months 38% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.
How accurate are Wall Street analyst price targets?
Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.
Should I follow Mayank Mamtani's stock ratings?
Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.
How does Bullish Whales score analyst accuracy?
Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.
How does Mayank Mamtani rank among Wall Street analysts?
Mayank Mamtani ranks number 4 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.